Epstein-Barr_JJ
virus_NN
binding_NN
to_TO
CD21_NN
activates_VBZ
the_DT
initial_JJ
viral_JJ
promoter_NN
via_IN
NF-kappaB_NN
induction_NN
._.

Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
,_,
an_DT
oncogenic_JJ
human_JJ
herpesvirus_NN
,_,
binds_VBZ
to_TO
and_CC
infects_VBZ
normal_JJ
human_JJ
B_NN
lymphocytes_NNS
via_IN
CD21_NN
,_,
the_DT
CR2_NN
complement_NN
receptor_NN
._.

Studies_NNS
of_IN
the_DT
mechanisms_NNS
that_WDT
enable_VBP
EBV_NN
to_TO
infect_VB
nonactivated_JJ
,_,
noncycling_JJ
B_NN
cells_NNS
provide_VBP
compelling_JJ
evidence_NN
for_IN
a_DT
sequence_NN
of_IN
events_NNS
in_IN
which_WDT
EBV_NN
binding_NN
to_TO
CD21_NN
on_IN
purified_VBN
resting_VBG
human_JJ
B_NN
cells_NNS
rapidly_RB
activates_VBZ
the_DT
NF-kappaB_NN
transcription_NN
factor_NN
,_,
which_WDT
,_,
in_IN
turn_NN
,_,
binds_VBZ
to_TO
and_CC
mediates_VBZ
transcriptional_JJ
activation_NN
of_IN
Wp_NN
,_,
the_DT
initial_JJ
viral_JJ
latent_JJ
gene_NN
promoter_NN
._.

Thus_RB
,_,
EBV_NN
binding_NN
to_TO
its_PRP$
cellular_JJ
receptor_NN
on_IN
resting_VBG
B_NN
cells_NNS
triggers_VBZ
an_DT
NF-kappaB-dependent_JJ
intracellular_JJ
signaling_NN
pathway_NN
which_WDT
is_VBZ
required_VBN
for_IN
infection_NN
._.

